Skip to Main Navigation

Drug-resistant infections : a threat to our economic future : executive summary (Inglês)

This report examines the economic and development consequences of antimicrobial resistance(AMR)—the capacity that disease-causing microorganisms acquire to resist the drugs we've createdto fight them. The report uses World Bank Group economic simulation tools to put a price tag onAMR's destructive impacts on the global economy from 2017 through 2050, if adequate measuresaren't taken to contain the AMR threat. The report highlights actions low- and middle-income countries and their development partners can take to counter AMR, and estimates the investment required. It shows that putting resources into AMR containment now is one of the highest-yield investments countries can make. Antimicrobials are drugs that destroy disease-causing microbes, also called pathogens, such as certain bacteria, viruses, parasites, and fungi. The most familiar and important antimicrobials are antibiotics, which treat bacterial infections. Other antimicrobials combat viral and parasitic diseases, such as AIDS and malaria. Since their use began some 70 years ago, antimicrobials have saved hundreds of millions of lives.

Detalhes

  • Autor

    Jonas,Olga B., Irwin, Alec, Berthe,Franck Cesar Jean, Le Gall,Francois G., Marquez,Patricio V.

  • Data do documento

    2017/03/01

  • TIpo de documento

    Documento de Trabalho

  • No. do relatório

    114679

  • Nº do volume

    1

  • Total Volume(s)

    2

  • País

    Mundo,

  • Região

    Regiões Mundiais,

  • Data de divulgação

    2017/04/28

  • Disclosure Status

    Disclosed

  • Nome do documento

    executive summary

  • Palavras-chave

    tragedy of the commons;gains in life expectancy;Infection Prevention and Control;cost of medical care;global gross domestic product;School of Public Health;per capita term;health care facilities;health care facility;global public good;animal production system;basic hygiene practice;access to water;health care settings;net present value;public health benefits;civil society partner;point of care;Health System Strengthening;health system reform;health emergency preparedness;role of water;sanitation and hygiene;accelerated economic growth;private health care;health service provider;innovation and learning;disparities in access;country case study;agricultural research center;quality of care;recommendations for action;Public Health Emergency;fisheries and aquaculture;infectious disease surveillance;privileges and immunity;spread of pathogen;health care practice;global financial crisis;trade in livestock;collapse of fishery;national action plan;development finance institution;sustainable resource management;safe drinking water;spread of infection;access to sanitation;global action plan;health information system;health care expenditure;Learning and Innovation Credit;investment framework;Livestock Production;health systems;development partner;antimicrobial drug;antimicrobial resistance;antibiotic;health facility;global economy;surveillance system;destructive impact;price tag;regional network;laboratory capacity;integrated strategy;knowledge production;small farmer;bacterial infection;animal protein;surveillance network;hand hygiene;investment cost;environmental science;coordinated action;livestock sector;animal population;multilateral agency;innovative models;sanitation facility;differential impact;labor income;real export;quantitative targets;scientific expert;acute phase;numerical targets;parasitic disease;evolutionary change;Economic Inequality;agriculture system;private benefit;antimicrobial treatment;public authority;investment option;global business;company profits;finance flow;health research;multidisciplinary research;investment lending;urban development;screening tool;Disaster Risk;sales volume;implementing policy;drug resistance;ongoing work;technological innovation;sanitation investment;broad consensus;prudent use;global health;research consortium;Population Sector;medical device;global innovation;research institution;human consumption;production method;insurance mechanism;agriculture sector;investment standard;comparative advantage;safety criterion;research institutions;pharmaceutical company;private producer;government regulation;veterinary service;veterinary Services;resource mobilization;operational practices;private source;national capacity;Public-Private Partnership;new market;food animal;data system;regulatory capacity;fair financing;evaluation result;investment opportunities;international community;regional laboratory;surveillance capacity;accreditation process;Equitable Finance;access gap;payment finance;prevention program;preventing infection;microbial threat;health challenge;health workforce;veterinary public;clinical laboratory;primary purpose;national policy;hygiene measures;disease burden;reducing inequality;global development;extreme poverty;eliminating poverty;investment policy;global benefit;investment case;annual investment;biotech firms;political action;strategic guidance;naval academy;local researcher;consumer protection;Animal Husbandry;professional education;drug-resistant strains;university hospital;copyright owner;sole responsibility;administrative support;commercial purpose;original work;international research;global agenda;veterinary training;stewardship programs;research collaboration;conservative approach;political momentum;clean water;livestock productivity;

Downloads

COMPLETAR RELATÓRIO

Versão oficial do documento (pode conter assinaturas, etc.)

  • PDF oficial
  • TXT*
  • Total Downloads** :
  • Download Stats
  • *A versão do texto é um OCR incorreto e está incluído unicamente em benefício de usuários com conectividade lenta.